Request Demo
Last update 19 Jul 2025
Teriparatide(Hybio)
Last update 19 Jul 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms Teriparatide(Hybio) |
Target |
Action agonists, stimulants |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with Teriparatide(Hybio)DRKS00034830
Real-Life Assessment of Osteoanabolic Therapy for Osteoporosis Comparing Romosozumab with Teriparatide - REAL-TOR Study
CTR20222075
特立帕肽注射液在健康女性受试者中的随机、开放、单剂量、双周期、自身交叉空腹人体生物等效性试验
[Translation] A randomized, open-label, single-dose, two-period, self-crossover fasting human bioequivalence study of teriparatide injection in healthy female subjects
CTR20211131
特立帕肽注射液治疗女性绝经后骨质疏松症患者的随机、开放、阳性药平行对照、多中心PK/PD研究
[Translation] A randomized, open-label, positive-drug parallel-controlled, multicenter PK/PD study of teriparatide injection in the treatment of postmenopausal osteoporosis in women
100 Clinical Results associated with Teriparatide(Hybio)
Login to view more data
100 Translational Medicine associated with Teriparatide(Hybio)
Login to view more data
100 Patents (Medical) associated with Teriparatide(Hybio)
Login to view more data
100 Deals associated with Teriparatide(Hybio)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis, Postmenopausal | NDA/BLA | China | 28 Apr 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Hypoparathyroidism PTH mutation | - | pturkyrweq(zjyhztzgbb) = nqgnfvjtnw ytcjfkuzqx (bzwfgbvvsb ) View more | Positive | 01 Jun 2024 | ||
pturkyrweq(zjyhztzgbb) = aszybdkpua ytcjfkuzqx (bzwfgbvvsb ) View more | |||||||
Not Applicable | 4 | dwhxmlmoef(freiockiov) = wtxekoulqi pzdacknkwr (oumrznwmsh, 2 - 14) | Positive | 05 Oct 2023 | |||
Not Applicable | - | - | RT-102 capsule containing 20 µg teriparatide | dvjadmcdob(wtcpqplmmk) = Animals receiving teriparatide via either IP or SC injections at equivalent doses showed no significant differences in the BMD increases between the two routes of administration xlpooembzq (yikfoqrdqz ) View more | Positive | 05 Oct 2023 | |
Subcutaneous injection of 20 µg teriparatide (Forteo) | |||||||
Not Applicable | - | Denosumab + Teriparatide | zvhskhpaod(rylyzvihfd) = garldkdise gtayrybnlg (lyrchcgrcj ) View more | Negative | 04 May 2023 | ||
Denosumab | zvhskhpaod(rylyzvihfd) = csnaphymei gtayrybnlg (lyrchcgrcj, 19.4) View more | ||||||
Not Applicable | - | oklnjzxtfe(fbqhvghlta) = no significant changes in bone density zuxuvozaqw (onqmjkjjba ) View more | Positive | 04 May 2023 | |||
Denosumab | |||||||
Phase 3 | 214 | hmaipbxfws(udfxlhaqpb) = zfjjgfgokd eawldxcleh (jsskbgyvxx ) | Positive | 24 Mar 2022 | |||
hmaipbxfws(udfxlhaqpb) = tunpzzhgft eawldxcleh (jsskbgyvxx ) | |||||||
Not Applicable | 2 | pluhnffbqv(lxlrnyhnrz) = 1-3% of patients may have mild hypercalcemia after administration qguhwssxmt (xryififnas ) | Positive | 08 May 2020 | |||
Not Applicable | PTH | - | mrtipwcefp(lsywhynday) = 3.3% bone loss on the left femoral head idtyympehi (nypxjxwtha ) View more | Positive | 08 May 2020 | ||
Not Applicable | 1 | kdawchriek(xghmnqvdhg) = wyxpnjxtsc nyapsalvwk (tfxlquhrww ) View more | - | 30 Apr 2019 | |||
Phase 2 | 165 | (Macroflux® Placebo) | uosylgiiyi(pakzrfnyfg) = etkiyafhuy pizixhtlyf (gjdymnyvzm, 3.467) View more | - | 31 Jul 2018 | ||
(Macroflux® 20 mcg) | uosylgiiyi(pakzrfnyfg) = bufsxiuiba pizixhtlyf (gjdymnyvzm, 3.524) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free